Pharmaceutical Formulations (Small Scale) Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Pharmaceutical formulations (small scale) sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹3.1 crore - ₹46 crore CapEx this DPR captures:

• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

The Indian pharmaceutical formulations sector is structurally bifurcated into a small cadre of large-scale multinational corporations that dominate high-value export markets and a vast MSME ecosystem that handles the bulk of domestic generic formulation production and contract manufacturing. Approximately 77 percent of India's pharmaceutical manufacturing units focus on generic formulations, with the MSME segment comprising roughly 8,500 of the total 10,500 units. This heavy MSME concentration creates a deeply fragmented industry where micro and small enterprises collectively serve a domestic market supported by approximately 6 lakh stockists and a wide retail infrastructure network.

Geographically, the sector is organized around 118 active pharmaceutical clusters spanning 19 states and union territories, with the Western region hosting 65 clusters, the Southern region 26, the Northern and Central regions 23, the Eastern region 3, and the North-Eastern region 1. Maharashtra leads state-level distribution with 40 clusters, followed by Gujarat, reflecting the concentrated industrial geography of small-scale pharmaceutical manufacturing. Small-scale formulation units typically operate with batch sizes ranging from under 2 kilograms to 20 kilograms, catering primarily to preclinical and early-phase clinical study requirements, while the broader formulation segment accounts for the majority share of manufacturing activity across the MSME landscape.

The Contract Development and Manufacturing Organization (CDMO) market, which heavily relies on small-scale manufacturing capacity, was valued at USD 8.52 billion in 2025 and is projected to reach USD 16.53 billion by 2034, with small molecules holding a dominant 67.2 percent share of that market.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth

Small-scale pharmaceutical manufacturing in 2025 and 2026 is characterized by a decisive technological shift toward continuous processing, modular facility design, and AI-driven precision manufacturing. Continuous Manufacturing (CM) systems integrate synthesis, processing, and real-time monitoring within streamlined production lines, enabling significantly smaller facility footprints and reduced cycle times compared to traditional batch processes. The global pharmaceutical continuous manufacturing market is expanding at an 11.20 percent compound annual growth rate from 2026 through 2032, reflecting rapid technology adoption.

Artificial intelligence is emerging as a transformative force, with the AI-enabled manufacturing market projected to scale from USD 0.88 billion in 2025 to USD 34.8 billion by 2040 at a CAGR of 27.8 percent. The broader smart manufacturing pharmaceutical market is estimated at USD 14.72 billion in 2026 and is projected to reach USD 32.49 billion by 2034 at a CAGR of 10.40 percent, indicating sustained investment in digitalization across manufacturing operations. However, small-scale units face significant scale-up challenges, as traditional batch processing requires scale-up factors of 5x to 20x to reach commercial production levels, creating substantial risk that Product Quality Attributes will drift between small-scale formulations and large-scale manufacturing.

Leading raw material suppliers including Roquette, BASF Pharma Solutions, Ashland, and JRS have implemented transparent sourcing frameworks and certifications such as Forest Stewardship Council and Programme for the Endorsement of Forest Certification to manage cellulose-based excipient supply chains, while Viatris has participated in fast-frequency responsive supply initiatives, demonstrating how material science and supply chain management are converging with manufacturing technology. Compounding pharmacy operations within the small-scale segment achieve net profit margins of approximately 20 percent, substantially higher than the 3 percent typical of commercial retail pharmacies, with compounding prescription gross margins targeting a baseline of 22 to 24 percent minimum.

Means of finance for a project in the ₹15-25 crore CapEx band should target a debt-equity ratio of 65:35 to optimise return on equity while maintaining debt service coverage ratios acceptable to lenders. For the ₹3.1-10 crore range, PMEGP loans up to ₹2 crore with 15% promoter contribution and 35% subsidy from KVIC can reduce effective borrowing requirement. SIDBI's pharma technology upgradation scheme offers term loans at 150 basis points below MCLR for WHO-GMP compliant facilities. For the ₹10-46 crore range, a consortium structure with SBI or HDFC Bank as lead arranger is recommended given the 5-year repayment timeline and project finance structure. State government schemes from Gujarat, Maharashtra, and Telangana offer 20-25% subsidy on capital equipment for projects located in pharmaceutical SEZs and industrial parks with CEPTAM status. Working capital requirements follow a 90-120 day cycle given the inventory hold for API materials (30 days), work-in-progress (15 days), finished goods quality release (45-60 days), and receivables from stockists (30-45 days). For US export-oriented units, the working capital cycle extends to 150 days given FDA lot-by-lot release documentation and export customs clearance timelines. The interest subvention scheme under the PhD (Pharmaceuticals and Health Sector) PLI provides 3% cash back on term loan interest for facilities exporting to regulated markets.

Small-scale pharmaceutical formulation manufacturers in India face a multi-dimensional risk environment spanning raw material volatility, regulatory compliance costs, scale-up challenges, workforce shortages, and pricing pressure. Raw material markets in 2026 are marked by geopolitical instability, shifting trade policies including U.S. Section 232 tariffs, and supply chain fragmentation, with BASF Pharma Solutions implementing a global price increase of up to 20 percent effective March 31, 2026, directly raising input costs for formulation units dependent on imported excipients and active ingredients.

The mandatory transition to revised Schedule M GMP norms imposes significant compliance capital requirements on MSME units already operating on thin margins. Scale-up inefficiencies represent a critical operational risk: traditional batch processing demands scale-up factors ranging from 5x to 20x to achieve commercial production levels, creating a high probability that Product Quality Attributes will drift between small-scale pilot or preclinical batches and large-scale manufacturing, potentially jeopardizing regulatory approvals and commercial viability. Workforce deficits affect 77 percent of manufacturers, with the industry requiring 19,000 new manufacturing jobs through 2034 against a projected employment base growing from 350,500 in 2024 to 369,500 in 2034, a 5.4 percent growth rate that lags behind industry expansion requirements.

Regulatory pricing risk is acute, with the NPPA controlling prices on 928 formulations and implementing ceiling price cuts of up to 25 percent on essential chronic medicines, as evidenced by Alkem Laboratories' 320-basis-point gross margin contraction in fiscal 2025 following price control imposition on its lead antihypertensive product. The 5 percent GST on general formulations, while reduced from 12 percent, still applies to a broad product base, while 18 percent GST on vitamins, health supplements, and OTC products compresses margins in those high-volume categories. Compounding operations, despite their 20 percent net profit margin advantage, face quality consistency risks inherent in small-batch customized manufacturing, and the broader industry faces the structural challenge of competing with large-scale manufacturers that benefit from economies of scale, deeper regulatory compliance resources, and stronger export market positioning.